Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
University Hospital, Basel, Switzerland |
---|---|
Information provided by: | University Hospital, Basel, Switzerland |
ClinicalTrials.gov Identifier: | NCT00313092 |
The aim of the study is to determine if plasma matrix-metalloproteinase activity can predict glaucoma in patients with OSAS and if the level of plasma matrix-metalloproteinase activity will decrease after one month of nCPAP-treatment.
Condition | Intervention |
---|---|
Obstructive Sleep Apnoe Syndrome Glaucoma |
Device: nCPAP treatment |
Study Type: | Observational |
Study Design: | Case-Only, Prospective |
Official Title: | Does Plasma Matrix-Metalloproteinase Activity Predict Glaucomas in Patients With OSAS (Obstructive Sleep Apnea Syndrome) and Does the Level of Plasma Matrix-Metalloproteinase Activity Decrease After One Month of nCPAP-Treatment |
plasma
Estimated Enrollment: | 60 |
Study Start Date: | January 2005 |
Estimated Study Completion Date: | September 2008 |
Glaucoma is a leading cause of blindness world-wide. Chronic primary open-angle glaucoma is the most common form among Caucasian patients. The key feature of glaucoma is damage to the optic nerve head, which is not necessarily related to an increased intraocular pressure. The prevalence of glaucoma among the patients with sleep apnoea was 7,2%: normal-tension glaucoma 2,9%, primary open-angle glaucoma 4,3%. The prevalence of obstructive sleep apnoea syndrome (OSAS) is around 4-10% for men and 2-4% for women. Matrix metalloproteinases (MMPs) substrates include essentially all extracellular matrix components as well as a wide array of molecules involved in intracellular adhesion, cell-matrix interaction, and cell signalling. However, MMPs effects are not restricted to extracellular matrix degradation. The prevalence of increased MMP in patients with OSAS and its predicting value for an additional glaucoma are not known. Further, we do not know if treatment of OSAS with nasal continuous positive air pressure(nCPAP) can decrease the MMP activity. With this study, we want to determine the prevalence of MMP activity and the prevalence of glaucoma in patients with OSAS. Further, we want to investigate if a nCPAP treatment period of four weeks decreases the MMP activity.
Ages Eligible for Study: | 18 Years to 95 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Patients with sleep apnoe syndrom
Inclusion Criteria:
Exclusion Criteria:
Contact: Jörg D Leuppi, MD | +41 61 265 8787 | leuppij@uhbs.ch |
Switzerland, BS | |
University Hospital Basel, Eye Clinic | Recruiting |
Basel, BS, Switzerland, 4031 | |
Contact: Selim Orgül, MD 141 61 265 8787 sorguel@uhbs.ch |
Study Director: | Selim Orgül, MD | University Eye Clinic Basel |
Responsible Party: | University Hospital, Basel, Switzerland ( Selim Orgul ) |
Study ID Numbers: | 045-LEJ-2004-002 |
Study First Received: | April 10, 2006 |
Last Updated: | January 14, 2008 |
ClinicalTrials.gov Identifier: | NCT00313092 |
Health Authority: | Switzerland: Swissmedic |
OSAS glaucoma MMP |
Sleep Apnea Syndromes Respiratory Tract Diseases Glaucoma Apnea Eye Diseases Respiration Disorders |
Sleep Apnea, Obstructive Dyssomnias Sleep Disorders Sleep Disorders, Intrinsic Hypertension Ocular Hypertension |
Pathologic Processes Disease Syndrome Nervous System Diseases |